MedTrace Logo

The Physiological Effects of FGF21 on Alcohol Preference and Glucose Metabolism

NCT04232033 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-12-09

No results posted yet for this study

Summary

The primary objective is to evaluate taste preferences for alcohol during an intravenous infusion of the naturally occurring hormone fibroblast growth factor-21 (FGF21) and placebo (i.e. saline), respectively, in 20 healthy subjects. Secondary endpoints are to evaluate the effects of exogenous FGF21 (compared to placebo) on resting energy expenditure, preference for salt, sour and bitter taste qualities, sensations of hunger, thirst, appetite, satiety, headache and nausea, and makers of glucose metabolism (e.g. plasma/serum concentrations of glucose, C-peptide, insulin and glucagon).

Conditions

  • Fibroblast Growth Factor 21
  • Tast Perference

Interventions

OTHER

Fibroblast growth factor 21 infusion

Infusion of Fibroblast growth factor 21

OTHER

Placebo infusion (saline)

Infusion of Saline

Sponsors & Collaborators

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Amalie R Lanng, Dr. · Center for Clinical Metabolic Research, Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2022-06-14
Completion
2024-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232033 on ClinicalTrials.gov